Pacer Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Pacer Advisors’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-280	Closed	-$15K	–	2385
2021 Q4	$15K	Sell	280 -140	-33%	-$7.3K	﹤0.01%	2171
2021 Q3	$22K	Sell	420 -518	-55%	-$30.8K	﹤0.01%	1415
2021 Q2	$65K	Buy	938 +100	+12%	+$7.63K	﹤0.01%	1366
2021 Q1	$65K	Sell	838 -84	-9%	-$7.74K	﹤0.01%	1402
2020 Q4	$91K	Buy	922 +464	+101%	+$56.7K	﹤0.01%	1376
2020 Q3	$65K	Buy	+458	New	+$76.4K	﹤0.01%	1293
2020 Q1	–	Sell	-2,393	Closed	-$495K	–	853
2019 Q4	$495K	Buy	2,393 +1,055	+79%	+$195K	0.02%	783
2019 Q3	$204K	Buy	+1,338	New	+$219K	﹤0.01%	1088

Other funds holding LKFT

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pacer Advisors's LKFT Position: Q1 2022 in Review

Pacer Advisors sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q1 2022, closing a stake of 280 shares — an estimated $15K sold.

Pacer Advisors first reported a position in LKFT in Q3 2019 and held it in 8 quarters. The position peaked at $495K in Q4 2019. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2022.

Pacer Advisors reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q1 2022 after selling out during the quarter.
Pacer Advisors sold 280 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2022, an estimated $15K.
Pacer Advisors first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2019 and held it in 8 quarters.
Pacer Advisors's Lakefront Biotherapeutics American Depositary Shares position peaked at $495K in Q4 2019.
90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2022.

Based on Pacer Advisors's 13F filing for Q1 2022, filed 5 Apr 2022.